Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloraprep vs Aqueous Chlorhexidine for Catheter-related Bacteremia
NCT03489512Phase 4
Key facts
- Status
- Withdrawn
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Sponsor
- Health Research Institute Hospital La Fe
- Modality
- Small Molecules
- Conditions
- Bacteremia
01
Overview
Phase 4, open-label trial of chlorhexidine + alcohol in Bacteremia (2 arms), sponsored by Health Research Institute Hospital La Fe. Primary endpoint: Incidence of catheter-related bacteremia. Planned start Oct 2019; status: withdrawn.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Chloraprep Arm
2% chlorhexidine gluconate with 70% isopropyl alcohol.
Aqueous Chlorhexidine Arm
2% aqueous base chlorhexidine.
03
Endpoints
Primary
Incidence of catheter-related bacteremia
Secondary
Incidence of pericatheter skin colonization
Incidence of colonization of the central venous catheter
Beyond the preview
Go deeper on NCT03489512.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489512.